白皮书:针对耐药病原体、窄谱适应症及未满足需求开发抗菌药物
尽管抗菌药物研发取得进展,仍亟需新的可行路径来开发治疗耐药细菌感染者的抗菌药物。耐药革兰阴性杆菌感染继续导致不可接受的发病率和死亡率。本文倡导一种新颖且务实的方法,并提出可行的试验设计,以支持开展窄谱、针对特定病原体的临床试验并最终批准急需的新型抗菌药物。
要点
- 耐药革兰阴性杆菌感染发病率和死亡率仍居高不下。
- 传统非劣效试验聚焦单一感染部位,可能不适用于耐药菌研究。
- 提出窄谱、病原体特异性临床试验的可行设计以加速审批。
核心结论
- 倡导新颖务实方法,提出可行试验设计以支持窄谱、病原体特异性临床试验并批准急需抗菌药物。
研究设计与样本
- 白皮书(立场文件),由多方利益相关者参与制定共识,未报告系统检索方法或样本量。
主要发现
- 耐药革兰阴性杆菌感染继续导致不可接受的发病率和死亡率。
- 历史抗菌药物非劣效试验聚焦单一感染部位(如复杂性尿路感染、腹腔感染),可能不是最优且常不可行。
临床怎么用
- 可采用窄谱、病原体特异性临床试验设计开展抗菌药物研究,以支持审批。
局限性
- 原文未报告具体试验设计细节、样本量或统计阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite progress in antimicrobial drug development, a critical need persists for new, feasible pathways to develop antibacterial agents to treat people infected with drug-resistant bacteria. Infections due to resistant gram-negative bacilli continue to cause unacceptable morbidity and mortality rates. Antibacterial agents have been historically studied in noninferiority clinical trials that focus on a single site of infection (eg, complicated urinary tract infections, intra-abdominal infections), yet these designs may not be optimal, and often are not feasible, for study of infections caused by drug-resistant bacteria. Over the past several years, multiple stakeholders have worked to develop consensus regarding paths forward with a goal of facilitating timely conduct of antimicrobial development. Here we advocate for a novel and pragmatic approach and, toward this end, present feasible trial designs for antibacterial agents that could enable conduct of narrow-spectrum, organism-specific clinical trials and ultimately approval of critically needed new antibacterial agents.
引用
- Boucher HW, Ambrose PG, Chambers HF, et al. White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs. J Infect Dis. 2017. PMID: 28475768. doi:10.1093/infdis/jix211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。